ArticleThe American journal of pathology2002
Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas.
Article in The American journal of pathology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 91 citations in OpenAlex.
- High interobserver variability of PTEN immunohistochemistry defining PTEN status in low- to intermediate-risk prostate cancer: results of the first German ring trial.Virchows Archiv : an international journal of pathology · 2025Article
- The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages.International journal of molecular sciences · 2025Review
- Post-Translational Regulation of ARF: Perspective in Cancer.Biomolecules · 2020Review
- Dual Role of the Alternative Reading Frame ARF Protein in Cancer.Biomolecules · 2019Review
- Regulatory Network of ARF in Cancer Development.Molecules and cells · 2018Review
- Clinical implications of PTEN loss in prostate cancer.Nature reviews. Urology · 2018Review
- Identifying aggressive prostate cancer foci using a DNA methylation classifier.Genome biology · 2017Article
- New and Emerging Diagnostic and Prognostic Immunohistochemical Biomarkers in Prostate Pathology.Advances in anatomic pathology · 2017Review
- Dynamics of ARF regulation that control senescence and cancer.BMB reports · 2016Review
- Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2016Article
- Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression.Carcinogenesis · 2015Review
- Heterogeneity of DNA methylation in multifocal prostate cancer.Virchows Archiv : an international journal of pathology · 2015Article
- PTEN deficiency mediates a reciprocal response to IGFI and mTOR inhibition.Molecular cancer research : MCR · 2014Article
- ETV1 positively regulates transcription of tumor suppressor ARF.Cancer biology & therapy · 2013Article
- Genomic Rearrangements of PTEN in Prostate Cancer.Frontiers in oncology · 2013Review
- Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer.PloS one · 2013Article
- DNA methylation in promoter region as biomarkers in prostate cancer.Methods in molecular biology (Clifton, N.J.) · 2012Article
- Qualitative and quantitative promoter hypermethylation patterns of the P16, TSHR, RASSF1A and RARβ2 genes in papillary thyroid carcinoma.Medical oncology (Northwood, London, England) · 2011Article
- ROS generation via NOX4 and its utility in the cytological diagnosis of urothelial carcinoma of the urinary bladder.BMC urology · 2011Article
- Cyclooxygenase 2-dependent and independent activation of Akt through casein kinase 2α contributes to human bladder cancer cell survival.BMC urology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To elucidate the role of p53/p16(INK4a)/RB1 pathways in prostate carcinogenesis, we analyzed the p14(ARF), p16(INK4a), RB1, p21(Waf1), p27(Kip1), PTEN, p73, p53, and MDM2 gene status of multiple areas within 16 histologically heterogeneous prostate carcinomas using methylation-specific polymerase chain reaction, differential polymerase chain reaction, and immunohistochemistry. All focal areas examined had Gleason scores ranging from 1 to 5. Methylation of either PTEN or p73 was undetected in any sample, whereas expression of MDM2 seemed to be an independent event within small foci of 4 of 16 tumors. Loss of p14(ARF), p16(INK4a), RB1, and p27(Kip1) expression correlated with homozygous deletion or promoter hypermethylation. One carcinoma showed co-deletion of both p14(ARF) and p16(INK4a) in two of five areas examined; two areas within another tumor demonstrated concurrent hypermethylation of the promoter regions of the same genes. Focal hypermethylation of RB1, p21(Waf1), and p27(Kip1) was detected within two, two, and three tumors, respectively. These findings indicate that both genetic and epigenetic events occur independently in intratumor foci and further suggest hypermethylation-induced loss of gene function may be as critical as specific genetic mutations in prostate carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.